Clinical Trial Update: Bevacizumab Intravitreal for Myopic Choroidal Neovascularization [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating intravitreal bevacizumab for myopic choroidal neovascularization has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myopic Choroidal Neovascularization

Drugs mentioned

• Bevacizumab (bevacizumab)

Snippet

Sponsor: Instituto de Olhos de Goiania | Conditions: Myopic Choroidal Neovascularization | Phase 4 | Status: COMPLETED